Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Incyte Corporation.

Advances In™ Cholangiocarcinoma: The Emerging Role of Immunotherapeutic and Targeted Approaches

Release Date: September 28, 2020
Expiration Date: September 28, 2021

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of cholangiocarcinoma, with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of diagnosis and molecular testing, clinical trial data, current and emerging treatment strategies, and management of treatment-related toxicities will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Incyte Corporation.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward oncologists, gastroenterologists, and hepatologists who treat patients with cholangiocarcinoma. Pathologists, histologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of cancer will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Outline appropriate genomics and molecular testing strategies to optimize diagnosis and treatment plans for patients with cholangiocarcinoma
  • Consider newly approved and emerging targeted therapeutic strategies that can be administered in the clinical management of patients with cholangiocarcinoma
  • Implement emerging strategies from recent and ongoing trials testing novel immunotherapies and targeted therapies for the treatment of patients with cholangiocarcinoma

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Andrew X. Zhu, MD, PhD
Andrew X. Zhu, MD, PhD
Director, Liver Cancer Research
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: Eli Lilly, Bayer, Merck, Sanofi, Eisai, Exelixis, Roche.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By